1. GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use
   Konstantinos Arvanitakis et al, 2023, Current Obesity Reports CrossRef
2. Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
   Tianyu Wang et al, 2024, Frontiers in Pharmacology CrossRef
3. Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
   Haiqiang Sang et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
4. Circadian secretion rhythm of GLP-1 and its influencing factors
   Chuanfeng Liu et al, 2022, Frontiers in Endocrinology CrossRef
5. Fibroblast involvement in cardiac remodeling and repair under ischemic conditions
   Zenaida Ceauşu et al, 2021, Experimental and Therapeutic Medicine CrossRef
6. Assessment of Cardiovascular Risk Factors and Their Interactions in the Risk of Coronary Heart Disease in Patients with Type 2 Diabetes with Different Weight Levels, 2013–2018
   Chenchen Wang et al, 2021, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy CrossRef
7. Diabetes mellitus: Plasticizers and nanomaterials acting as endocrine‑disrupting chemicals (Review)
   Mihaela Tuculina et al, 2022, Experimental and Therapeutic Medicine CrossRef
8. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
   Rafael Tamayo-Trujillo et al, 2024, Frontiers in Nutrition CrossRef
9. The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
   Rishi Jobanputra et al, 2023, Obesity Reviews CrossRef
10. SIBUTRAMINA E LIRAGLUTIDA NA TERAPÊUTICA DA OBESIDADE
    Jaianny Chaves Braga et al, 2024, Revista Contemporânea CrossRef
11. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
    Manoj Kumar Mahapatra et al, 2022, Reviews in Endocrine and Metabolic Disorders CrossRef
12. Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet
    Li Zhao et al, 2022, Frontiers in Nutrition CrossRef
13. Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective
    Jing Cui et al, 2021, Frontiers in Cardiovascular Medicine CrossRef
14. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
    Yaohui Jiang et al, 2021, Frontiers in Pharmacology CrossRef
15. Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
    Omar S. Alkhezi et al, 2023, Obesity Reviews CrossRef
16. Semaglutide-eye-catching results
    Maja Cigrovski Berkovic et al, 2023, World Journal of Diabetes CrossRef
17. Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
    Alexander C. Martins et al, 2024, Exploration of Drug Science CrossRef
18. Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
    Michele Correale et al, 2021, Heart Failure Reviews CrossRef
19. Effects of Probiotic Supplementation on Inflammatory Markers and Glucose Homeostasis in Adults With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Li-Na Ding et al, 2021, Frontiers in Pharmacology CrossRef